Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Ochi A"'
Autor:
Siro Miura, Kazuto Takeuchi, Yuichi Ikeda, Takashi Haro, Yoshihiro Yakushijin, Kazushi Tanimoto, Kensuke Senzaki, Shogo Nabe, Toshiki Ochi, Jun Yamanouchi, Masaki Maruta, Jun-ichi Kato, Katsuto Takenaka
Publikováno v:
Annals of Oncology. 32:S356
Autor:
Satoshi Oizumi, Kyoichi Okishio, Toru Kumagai, Hiroaki Tsukamoto, Ryo Morita, Yuichiro Ohe, Makoto Nishio, Keisuke Aoe, Junichi Simizu, Keiko Mizuno, Keisuke Tomii, Kenya Ochi, Osamu Hataji, Hiroshi Tanaka, Haruhiro Saito, Young Hak Kim, Hiroshi Sakai, Hirotoshi Hoshiyama, Makiko Yomota, Osamu Kanai, Kayoko Kibata
Publikováno v:
Annals of Oncology. 30:vi113
Background Since its approval in December 2015, nivolumab has been widely used as a second-line treatment for non-small cell lung cancer (NSCLC) patients regardless of tumor PD-L1 expression or histology. However, the relationship between nivolumab e
Autor:
Osamu Kanai, Toru Kumagai, Makiko Yomota, Yuichiro Ohe, Hiroshi Tanaka, Kenya Ochi, Hiroshi Sakai, Young Hak Kim, Ryo Morita, Satoshi Oizumi, Hiroaki Tsukamoto, Hirotoshi Hoshiyama, Kyoichi Okishio, Kayoko Kibata, Makoto Nishio, Junichi Shimizu, Keisuke Aoe, Keiko Mizuno, Osamu Hataji, Keisuke Tomii, Haruhiro Saito
Publikováno v:
Annals of Oncology. 30:vi110
Background In December 2015, nivolumab was approved as treatment for previously treated NSCLC irrespective of PD-L1 expression or histology in Japan. There are few reports that include real-world data on large cohorts of patients from Japan. Method D
Autor:
Keiko Mizuno, Keisuke Tomii, Osamu Hataji, Keisuke Aoe, Satoru Kitazono, Kyoichi Okishio, Kenya Ochi, Makiko Yomota, Hiroshi Sakai, Yuichiro Ohe, Hiroshi Tanaka, Osamu Kanai, Kayoko Kibata, Junichi Shimizu, Haruhiro Saito, Hirotoshi Hoshiyama, Satoshi Oizumi, Hiroaki Tsukamoto, Ryo Morita, Young Hak Kim, Toru Kumagai
Publikováno v:
Annals of Oncology. 30:vi110
Background In December 2015, nivolumab was approved as treatment for previously treated NSCLC irrespective of PD-L1 expression or histology in Japan. There are few reports that include real-world data on large-scale cohorts of patients with special b
Autor:
Satoshi Oizumi, Hiroaki Tsukamoto, Keisuke Aoe, Yuichiro Ohe, Yong Hak Kim, Ryo Morita, Makoto Nishio, Osamu Hataji, Kayoko Kibata, Junichi Shimizu, Hiroshi Tanaka, Hirotoshi Hoshiyama, Makiko Yomota, Toru Kumagai, Osamu Kanai, Keisuke Tomii, Hiroshi Sakai, Kyoichi Okishio, Kenya Ochi, Keiko Mizuno, Haruhiro Saito
Publikováno v:
Annals of Oncology. 30:vi113
Background In December 2015, nivolumab was approved for previously treated advanced NSCLC irrespective of PD-L1 expression or histology in Japan. Real-world data can provide insights beyond the clinical trial, and in this analysis we study a large Ja
Autor:
Keisuke Aoe, Takuo Shibayama, Akihiro Bessho, K. Sugimoto, Naoyuki Nogami, Nagio Takigawa, Kenichiro Kudo, Nobukazu Fujimoto, Toshiyuki Kozuki, Katsuyuki Hotta, Takashi Ninomiya, Daisuke Minami, K. Kiura, Nobuaki Ochi, Kadoaki Ohashi, Shoichi Kuyama, Takafumi Kubo, Daijiro Harada
Publikováno v:
Annals of Oncology. 30:v626
Background In a phase I study, Afa (30 mg/body daily) plus Bev (15 mg/kg every 3 weeks) was well tolerated and had evidence of favorable disease control (Lung Cancer, 2018). We report an updated progression free survival (PFS), overall survival (OS)
Autor:
Naoyuki Nogami, K. Kiura, Nobuaki Ochi, Kenichi Chikamori, Akihiro Bessho, Nobukazu Fujimoto, Shoichi Kuyama, T. Umeno, G. Ikeda, Katsuyuki Hotta, Daizo Kishino, Daijiro Harada, Nagio Takigawa, Kiichiro Ninomiya
Publikováno v:
Annals of Oncology. 28:x139-x140
Autor:
Akihiro Bessho, Toshiyuki Kozuki, Daisuke Minami, Naoyuki Nogami, Shoichi Kuyama, K. Kiura, Daijiro Harada, K. Sugimoto, Keisuke Aoe, Takashi Ninomiya, Nobuaki Ochi, N. Fukamatsu, Kenichiro Kudo, Nobukazu Fujimoto
Publikováno v:
Annals of Oncology. 28:x129-x130
Autor:
Yoshihiro Yakushijin, Toshiki Ochi, Kazushi Tanimoto, Kazuto Takeuchi, Masaki Yasukawa, Takaaki Hato, Hiroaki Asai, Taichi Azuma, Jun Yamanouchi, Hiroshi Fujiwara, Yuuichi Ikeda
Publikováno v:
Annals of Oncology. 29:vii77
Publikováno v:
ResearcherID